These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Acid monoamine metabolites in the cerebrospinal fluid of Parkinsonian patients treated with levodopa alone or combined with a decarboxylase inhibitor. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1973; 9(6):349-62. PubMed ID: 4712542 [No Abstract] [Full Text] [Related]
3. Treatment of parkinsonism by amantadine and levodopa. Mawdsley C; Williams IR; Pullar IA; Davidson DL; Kinloch NE Clin Pharmacol Ther; 1972; 13(4):575-83. PubMed ID: 4557584 [No Abstract] [Full Text] [Related]
4. Amine metabolites in the cerebrospinal fluid in Parkinson's disease and the response to levodopa. Gumpert J; Sharpe D; Curzon G J Neurol Sci; 1973 May; 19(1):1-12. PubMed ID: 4715017 [No Abstract] [Full Text] [Related]
5. Treatment of Parkinson's disease with amantadine and L-Dopa. Rinne UK; Sonninen V; Siirtola T Eur Neurol; 1972; 7(4):228-40. PubMed ID: 4556618 [No Abstract] [Full Text] [Related]
6. The balance of biogenic amines as condition for normal behaviour. Birkmayer W; Danielczyk W; Neumayer E; Riederer P J Neural Transm; 1972; 33(2):163-78. PubMed ID: 4643007 [No Abstract] [Full Text] [Related]
7. Catecholamine metabolism during oral administration of levodopa. Hinterberger H; Andrews CJ Arch Neurol; 1972 Mar; 26(3):245-52. PubMed ID: 5061285 [No Abstract] [Full Text] [Related]
8. Levodopa combined with MK 486 (L-alpha methyldopahydrazine)--a peripheral decarboxylase inhibitor in Parkinson's disease. Andrews CJ; Somerville B Med J Aust; 1974 Mar; 1(12):429-32. PubMed ID: 4598384 [No Abstract] [Full Text] [Related]
9. Treatment of Parkinson's disease with L-DOPA and decarboxylase inhibitor. Rinne UK; Sonninen V; Sirtola T Z Neurol; 1972; 202(1):1-20. PubMed ID: 4114458 [No Abstract] [Full Text] [Related]
10. [Biochemistry of depression]. Matussek N J Neural Transm; 1972; 33(3):223-34. PubMed ID: 4565920 [No Abstract] [Full Text] [Related]
11. Methyldopahydrazine as an adjunct to L-dopa therapy in parkinsonism. Chase TN; Watanabe AM Neurology; 1972 Apr; 22(4):384-92. PubMed ID: 5062828 [No Abstract] [Full Text] [Related]
12. Treatment of Parkinson's disease with levodopa and Ro 4-4602. Barbeau A; Gillo-Joffroy L; Mars H Clin Pharmacol Ther; 1971; 12(2):353-9. PubMed ID: 4930866 [No Abstract] [Full Text] [Related]
13. L-DOPA, catecholamines, and behavior: a clinical and biochemical study in depressed patients. Goodwin FK; Murphy DL; Brodie HK; Bunney WE Biol Psychiatry; 1970 Oct; 2(4):341-66. PubMed ID: 4920729 [No Abstract] [Full Text] [Related]
14. Metabolism and clinical assessment of L-dopa in parkinsonism. Ericsson AD; McCann D; Sharpless N; Reveno W Neurology; 1970 Apr; 20(4):402. PubMed ID: 4935027 [No Abstract] [Full Text] [Related]
16. Levodopa in Parkinsonism: potentiation of central effects with a peripheral inhibitor. Papavasiliou PS; Cotzias GC; Düby SE; Steck AJ; Fehling C; Bell MA N Engl J Med; 1972 Jan; 286(1):8-14. PubMed ID: 4550085 [No Abstract] [Full Text] [Related]
17. [Treatment of Parkinsonism with L-dopa--with special reference to clinical effects, side effects and urinary metabolites of catecholamines]. Uono M; Tanabe H; Yano Y; Nakao K No To Shinkei; 1970 Sep; 22(9):1091-101. PubMed ID: 5536082 [No Abstract] [Full Text] [Related]